This technology relates in part to compositions and kits comprising nucleic acids, vectors, and cells that express HLA-J, as well as HLA-J proteins and peptides, and uses thereof, for example for medical treatments, vaccines and diagnosis.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C07K 14/74 - Major histocompatibility complex [MHC]
2.
HLA CLASS I MOLECULES IN IN VITRO FERTILIZATION AND FURTHER MEDICAL IMPLICATIONS
The present invention relates to a nucleic acid molecule, a vector, a host cell, or a protein or peptide, or any combination thereof for use in a method of increasing efficiency of embryonic implantation in an in vitro fertilization programme, (I) wherein the at least one nucleic acid molecule is selected from nucleic acid molecules (a) encoding a polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs 1 to 17, (b) comprising or consisting of the nucleotide sequence of any one of SEQ ID NOs 18 to 23, (c) encoding a polypeptide which is at least 85% identical, preferably at least 90% identical, and most preferred at least 95% identical to the amino acid sequence of (a), (d) consisting of a nucleotide sequence which is at least 95% identical, preferably at least 96% identical, and most preferred at least 98% identical to the nucleotide sequence of (b), (e) consisting of a nucleotide sequence which is degenerate with respect to the nucleic acid molecule of (d), (f) consisting of a fragment of the nucleic acid molecule of any one of (a) to (e), said fragment comprising at least 150 nucleotides, preferably at least 300 nucleotides, more preferably at least 450 nucleotides, and most preferably at least 600 nucleotides, and (g) corresponding to the nucleic acid molecule of any one of (a) to (f), wherein T is replaced by U, and (II) the vector comprises the nucleic acid molecule of (I); (III) the host cell is transformed, transduced or transfected with the vector of (II); and (IV) the at least one protein or peptide is selected from proteins or peptides being encoded by the nucleic acid molecule of (I); and wherein the method of increasing embryonic implantation efficiency comprises (i) contacting the nucleic acid molecule, vector, host cell, or protein or peptide, or any combination thereof with the unfertilized, fertilized oocyte, and/or preimplantation embryo prior to the transfer of the fertilized oocyte or preimplantation embryo to the uterus; or (ii) contacting the nucleic acid molecule, vector, host cell, or protein or peptide, or any combination thereof with the uterus prior to, simultaneously with and/or after the transfer of the fertilized oocyte or preimplantation embryo to the uterus; or (iii) systemically administering the nucleic acid molecule, vector, host cell, or protein or peptide, or any combination prior to, simultaneously with and/or after the transfer of the fertilized oocyte or preimplantation embryo to the uterus, preferably via injection, transdermal and/or vaginal administration.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/74 - Major histocompatibility complex [MHC]
3.
HLA-H, HLA-J, HLA-L, HLA-V AND HLA-Y AS THERAPEUTIC AND DIAGNOSTIC TARGETS
The present invention relates to a method for producing a medicament for the treatment or prevention of a tumor in a subject or a diagnostic agent for the detection of a tumor in a subject comprising (A) determining the expression of at least one nucleic acid molecule and/or at least one protein or peptide in a sample obtained from said subject, wherein the at least one nucleic acid molecule is selected from nucleic acid molecules (a) encoding a polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs 1 to 5, (b) comprising or consisting of the nucleotide sequence of any one of SEQ ID NOs 6 to 10, (c) encoding a polypeptide which is at least 85% identical, preferably at least 90% identical, and most preferred at least 95% identical to the amino acid sequence of (a), (d) consisting of a nucleotide sequence which is at least 95% identical, preferably at least 96% identical, and most preferred at least 98% identical to the nucleotide sequence of (b), (e) consisting of a nucleotide sequence which is degenerate with respect to the nucleic acid molecule of (d), (f) consisting of a fragment of the nucleic acid molecule of any one of (a) to (e), said fragment comprising at least 150 nucleotides, preferably at least 300 nucleotides, more preferably at least 450 nucleotides, and most preferably at least 600 nucleotides, and (g) corresponding to the nucleic acid molecule of any one of (a) to (f), wherein T is replaced by U, and wherein the at least one protein or peptide is selected from proteins or peptides being encoded by the nucleic acid molecule of any one of (a) to (g); and (B) producing a medicament capable of inhibiting the expression of the at least nucleic acid molecule and/or the at least one protein or peptide in the subject, if the at least one nucleic acid molecule and/or at least one protein or peptide is expressed in (A), and/or (B′) producing a diagnostic agent capable of detecting in vivo the sites of expression of the at least nucleic acid molecule and/or the at least one protein or peptide in the subject, if the at least one nucleic acid molecule and/or at least one protein or peptide is expressed in (A).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 14/74 - Major histocompatibility complex [MHC]
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/60 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances involving radioactive labelled substances
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
4.
DETERMINING INDIVIDUAL HLA PATTERNS, USE AS PROGNOSTICATORS, TARGET GENES AND THERAPEUTIC AGENTS
The present disclosure relates to in vitro methods of determining the individual HLA patterns (adult and/or embryonic) in body samples (tissue or blood samples) of cancer patients and/or patients suffering disorders related to autoimmune disease and to methods of stratifying said patients for tailored treatments. It further relates to corresponding kits and their uses, as well as to nucleic acid molecules as prognostic biomarkers for neoplastic disease such as cancer, autoimmune disease, infectious disease and conditions related to pregnancy. It also relates to therapeutic agents and to methods of producing therapeutic agents.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
5.
METHODS FOR DIAGNOSING THE EFFECTIVENESS OF ANTI-TUMOR TREATMENT
The present invention relates to a method for predicting whether a subject having a tumor responds to a tumor therapy selected from (i) an immunotherapy, (ii) a chemotherapy, (iii) an anti-hormonal therapy, and (iv) an anti-tyrosin kinase therapy, wherein the method comprises (A) determining the level(s) of at least one nucleic acid molecule and/or at least one protein or peptide in a sample obtained from said subject, wherein the at least one nucleic acid molecule is selected from nucleic acid molecules (a) encoding a polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs 1 to 6, (b) consisting of the nucleotide sequence of any one of SEQ ID NOs 7 to 12, (c) encoding a polypeptide which is at least 85% identical, preferably at least 90% identical, and most preferred at least 95% identical to the amino acid sequence of (a), (d) consisting of a nucleotide sequence which is at least 95% identical, preferably at least 96% identical, and most preferred at least 98% identical to the nucleotide sequence of (b), (e) consisting of a nucleotide sequence which is degenerate with respect to the nucleic acid molecule of (d), (f) consisting of a fragment of the nucleic acid molecule of any one of (a) to (e), said fragment comprising at least 150 nucleotides, preferably at least 300 nucleotides, more preferably at least 450 nucleotides, and most preferably at least 600 nucleotides, and (g) corresponding to the nucleic acid molecule of any one of (a) to (f), wherein T is replaced by U, and wherein the at least one protein or peptide is selected from proteins or peptides being encoded by the nucleic acid molecule of any one of (a) to (g); and (B) comparing the level(s) of (A) with the level(s) of the at least one nucleic acid molecule and/or the at least one protein or peptide in a sample obtained from one or more subjects that responded to one or more of the therapies of (i) to (ii) or a corresponding pre-determined standard, wherein increased level(s) of (A) as compared to the level(s) or pre-determined standard of (B) indicate(s) that the subject will not respond to the tumor therapy and substantially the same or decreased level(s) of (A) as compared to the level(s) of (B) indicate(s) that the subject will respond to the tumor therapy; or (B′) comparing the level(s) of (A) with the level(s) of the at least one nucleic acid molecule and/or the at least one protein or peptide in a sample obtained from one or more subjects that did not respond to one or more of the therapies of (i) to (iii) or a corresponding pre-determined standard, wherein decreased level(s) of (A) as compared to the level(s) or pre-determined standard of (B′) indicate(s) that the subject will respond to the tumor therapy and substantially the same or increased level(s) of (A) as compared to the level(s) of (B′) indicate(s) that the subject will not respond to the tumor therapy.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a nucleic acid molecule, a vector, a host cell, or a protein or peptide, or combinations thereof for use as an immunosuppressant, as a tumor vaccine or as a pregnancy promoter wherein (I) the nucleic acid molecule is (a) encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; or (b) consisting of the nucleotide sequence of SEQ ID NO: 2; or (c) encoding a polypeptide which is at least 70%, preferably at least 80% identical, more preferably at least 90% identical, and most preferred at least 95% identical to the amino acid sequence of SEQ ID NO: 1; or (d) consisting of a nucleotide sequence which is at least 70% identical, preferably at least 80% identical, more preferably at least 90% identical, and most preferred at least 95% identical to the nucleotide sequence of SEQ ID NO: 2; or (e) consisting of a nucleotide sequence which is degenerate with respect to the nucleic acid molecule of (d); or (f) a fragment of the nucleic acid molecule of any one of (a) to (e), said fragment comprising at least 150 nucleotides, preferably at least 300 nucleotides, more preferably at least 450 nucleotides, and most preferably at least 600 nucleotides; or (g) corresponding to the nucleic acid molecule of any one of (a) to (f), wherein T is replaced by U; (II) the vector comprises the nucleic acid molecule of (I); (III) the host cell is transformed, transduced or transfected with the vector of (II); and (IV) the protein or peptide being encoded by the nucleic acid molecule of (I).
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C07K 14/74 - Major histocompatibility complex [MHC]
7.
HLA-H, HLA-J, HLA-L, HLA-V AND HLA-Y AS THERAPEUTIC AND DIAGNOSTIC TARGETS
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
8.
IN VITRO FERTILIZATION AND FURTHER MEDICAL IMPLICATIONS
in vitroin vitro fertilization programme, (I) wherein the at least one nucleic acid molecule is selected from nucleic acid molecules (a) encoding a HLA-H, HLA-G, HLA- J, HLA-L, HLA-V, HLA-Y, HLA-E, HLA-F polypeptide or a polypeptide which is at least 85% identical, or consists of a fragment of the nucleic acid molecule comprising at least 150 nucleotides; and wherein the method of increasing embryonic implantation efficiency comprises (i) contacting the nucleic acid molecule, vector, host cell, or protein or peptide, or any combination thereof with the unfertilized, fertilized oocyte, and/or preimplantation embryo prior to the transfer of the fertilized oocyte or preimplantation embryo to the uterus; or (ii) prior to, simultaneously with and/or after the transfer of the fertilized oocyte or preimplantation embryo to the uterus; or (iii) systemically administering the nucleic acid molecule, vector, host cell, or protein or peptide.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 14/74 - Major histocompatibility complex [MHC]
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
9.
DETERMINING INDIVIDUAL HLA PATTERNS, USE AS PROGNOSTICATORS, TARGET GENES AND THERAPEUTIC AGENTS
in vitroin vitro methods of determining the individual HLA patterns (adult and/or embryonic) in body samples (tissue or blood samples) of cancer patients and/or patients suffering disorders related to autoimmune disease and to methods of stratifying said patients for tailored treatments. It further relates to corresponding kits and their uses, as well as to nucleic acid molecules as prognostic biomarkers for neoplastic disease such as cancer, autoimmune disease, infectious disease and conditions related to pregnancy. It also relates to therapeutic agents and to methods of producing therapeutic agents.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present invention relates to a HLA-H related nucleic acid molecule, a vector, a host cell, or a protein or peptide, or combinations thereof for use as an immunosuppressant, as a tumor vaccine or as a pregnancy promoter wherein (I) the nucleic acid molecule is (a) encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; or (b) consisting of the nucleotide sequence of SEQ ID NO: 2; or (c) encoding a polypeptide which is at least 70% identical to SEQ ID NO: 1; or (d) consisting of a nucleotide sequence which is at least 70% identical to the nucleotide sequence of SEQ ID NO: 2; or (e) consisting of a nucleotide sequence which is degenerate with respect to the nucleic acid molecule of (d); or (f) a fragment of the nucleic acid molecule of any one of (a) to (e), said fragment comprising at least 150 nucleotides; or (g) corresponding to the nucleic acid molecule of any one of (a) to (f), wherein T is replaced by U; (II) the vector comprises the nucleic acid molecule of (I); (III) the host cell is transformed, transduced or transfected with the vector of (II); and (IV) the protein or peptide being encoded by the nucleic acid molecule of (I).
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
C07K 14/74 - Major histocompatibility complex [MHC]
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
11.
METHODS FOR DIAGNOSING THE EFFECTIVENESS OF ANTI-TUMOR TREATMENT
The present invention relates to a method for predicting whether a subject having a tumor responds to a tumor therapy selected from (i) an immunotherapy, (ii) a chemotherapy, (iii) an anti-hormonal therapy, and (iv) an anti-tyrosin kinase therapy, wherein the method comprises (A) determining the level(s) of at least one nucleic acid molecule and/or at least one protein or peptide in a sample obtained from said subject, wherein the at least one nucleic acid molecule is selected from nucleic acid molecules (a) encoding a polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs 1 to 6, (b) consisting of the nucleotide sequence of any one of SEQ ID NOs 7 to 12, (c) encoding a polypeptide which is at least 85% identical, preferably at least 90% identical, and most preferred at least 95% identical to the amino acid sequence of (a), (d) consisting of a nucleotide sequence which is at least 95% identical, preferably at least 96% identical, and most preferred at least 98% identical to the nucleotide sequence of (b), (e) consisting of a nucleotide sequence which is degenerate with respect to the nucleic acid molecule of (d), (f) consisting of a fragment of the nucleic acid molecule of any one of (a) to (e), said fragment comprising at least 150 nucleotides, preferably at least 300 nucleotides, more preferably at least 450 nucleotides, and most preferably at least 600 nucleotides, and (g) corresponding to the nucleic acid molecule of any one of (a) to (f), wherein T is replaced by U, and wherein the at least one protein or peptide is selected from proteins or peptides being encoded by the nucleic acid molecule of any one of (a) to (g); and (B) comparing the level(s) of (A) with the level(s) of the at least one nucleic acid molecule and/or the at least one protein or peptide in a sample obtained from one or more subjects that responded to one or more of the therapies of (i) to (iii) or a corresponding pre-determined standard, wherein increased level(s) of (A) as compared to the level(s) or pre-determined standard of (B) indicate(s) that the subject will not respond to the tumor therapy and substantially the same or decreased level(s) of (A) as compared to the level(s) of (B) indicate(s) that the subject will respond to the tumor therapy; or (B') comparing the level(s) of (A) with the level(s) of the at least one nucleic acid molecule and/or the at least one protein or peptide in a sample obtained from one or more subjects that did not respond to one or more of the therapies of (i) to (iii) or a corresponding pre-determined standard, wherein decreased level(s) of (A) as compared to the level(s) or pre-determined standard of (B') indicate(s) that the subject will respond to the tumor therapy and substantially the same or increased level(s) of (A) as compared to the level(s) of (B') indicate(s) that the subject will not respond to the tumor therapy.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present invention relates to a nucleic acid molecule (a) encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1, (b) consisting of the nucleotide sequence of SEQ ID NO: 2, (c) encoding a polypeptide which is at least 70%, preferably at least 80% identical, more preferably at least 90% identical, and most preferred at least 95% identical to the amino acid sequence of SEQ ID NO: 1; (d) consisting of a nucleotide sequence which is at least 70% identical, preferably at least 80% identical, more preferably at least 90% identical, and most preferred at least 95% identical to the nucleotide sequence of SEQ ID NO: 2; (e) consisting of a nucleotide sequence which is degenerate with respect to the nucleic acid molecule of (d); (f) a fragment of the nucleic acid molecule of any one of (a) to (e), said fragment comprising at least 150 nucleotides, preferably at least 300 nucleotides, more preferably at least 450 nucleotides, and most preferably at least 600 nucleotides; or (g) corresponding to the nucleic acid molecule of any one of (a) to (f), wherein T is replaced by U.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C07K 14/74 - Major histocompatibility complex [MHC]
What are disclosed are a method for providing a medicament for treating a malignancy and also cell membranes provided thereby and the use thereof, in which method there is ascertainment of the individual communication structure between the malignancy and the immune system on the basis of a tissue sample containing cells of the malignancy via determination of a malignancy-specific expression pattern of histocompatibility antigens (human leukocyte antigen, HLA) at said tissue sample, there is masking or removal of at least such a portion of the expression pattern which is present at the cells of the tissue sample and which is capable of exerting an inhibitory effect on immunocompetent cells, and there is provision of an individual vaccine for inducing a specific immune response by lysis of those cells at which a portion of the expression pattern was masked or removed.
Methods for providing a medicament for the treatment of a malignant tumor taking into account the individually associated immune system, and also antibodies provided thereby and the use thereof, are disclosed, wherein the individual communication structure between the malignant tumor and the immune system is ascertained by determination of an expression pattern of embryonic HLA groups and by determination of a receptor type present on/in immunocompetent cells, and antibodies are provided of the type which specifically bind as ligands to the at least one determined receptor type and, as a result, block or mask the receptor such that the at least one portion of the expression pattern cannot bind there or can only bind there with lower action, but themselves do not inhibit the associated immunocompetent cell.
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
patents
